en
/
sv
About Elicera
Elicera in brief
Board
Management
Elicera's history
Immuno-oncology
What is immuno-oncology?
Oncolytic virus
CAR T-cell therapy
Technology
Strengths
iTANK-platform
ELC-100
ELC-201
ELC-301
ELC-401
Patents
Pipeline
Pipeline
Clinical trials
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
IPO
News
News
Press Releases
Events
Contact
en
/
sv
News
2021
2020
2019
2018
2016
2014
2013
June 10, 2021
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 9, 2021
Elicera Therapeutics' new issue heavily oversubscribed
Regulatory Press Release
Press Release
News
Read more
June 4, 2021
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 3, 2021
CEO-interview by Nyhetsbyrån Direkt
Regulatory Press Release
Press Release
News
Read more
May 31, 2021
Article in "Forskning och framsteg"
Regulatory Press Release
Press Release
News
Read more
May 24, 2021
Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
May 18, 2021
Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.
Regulatory Press Release
Press Release
News
Read more
May 17, 2021
Company presentation at "Aktiedagen Göteborg".
Regulatory Press Release
Press Release
News
Read more
April 27, 2021
Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
April 15, 2021
Biostock writes about Elicera and CAR T-cells
Regulatory Press Release
Press Release
News
Read more
March 22, 2021
Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera Therapeutics recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 8, 2021
Elicera Therapeutics invitation to company presentation (in Swedish)
Regulatory Press Release
Press Release
News
Read more
October 20, 2020
Daily Mail writes about Elicera
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
July 15, 2020
Immuno-Oncology News writes about Elicera's CAR T-cell program
Regulatory Press Release
Press Release
News
Read more
July 6, 2020
Financial Times writes about Elicera
Regulatory Press Release
Press Release
News
Read more
June 3, 2020
Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed
Regulatory Press Release
Press Release
News
Read more
April 23, 2020
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Regulatory Press Release
Press Release
News
Read more
April 2, 2020
Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers
Regulatory Press Release
Press Release
News
Read more
January 10, 2020
Funding from the Sjöberg Foundation
Regulatory Press Release
Press Release
News
Read more
November 13, 2019
Funding by the Swedish Cancer Society
Regulatory Press Release
Press Release
News
Read more
March 2, 2018
Status update by Uppsala University on the clinical phase I/II-study in NET
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
Swedish Public Radio interviews Professor Magnus Essand
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
The Medical Journal writes about a clinical study
Regulatory Press Release
Press Release
News
Read more
October 27, 2014
Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)
Regulatory Press Release
Press Release
News
Read more
June 15, 2013
Successful crowdfunding
Regulatory Press Release
Press Release
News
Read more
June 10, 2021
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 9, 2021
Elicera Therapeutics' new issue heavily oversubscribed
Regulatory Press Release
Press Release
News
Read more
June 4, 2021
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 3, 2021
CEO-interview by Nyhetsbyrån Direkt
Regulatory Press Release
Press Release
News
Read more
May 31, 2021
Article in "Forskning och framsteg"
Regulatory Press Release
Press Release
News
Read more
May 24, 2021
Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
May 18, 2021
Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.
Regulatory Press Release
Press Release
News
Read more
May 17, 2021
Company presentation at "Aktiedagen Göteborg".
Regulatory Press Release
Press Release
News
Read more
April 27, 2021
Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
April 15, 2021
Biostock writes about Elicera and CAR T-cells
Regulatory Press Release
Press Release
News
Read more
March 22, 2021
Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera Therapeutics recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 8, 2021
Elicera Therapeutics invitation to company presentation (in Swedish)
Regulatory Press Release
Press Release
News
Read more
October 20, 2020
Daily Mail writes about Elicera
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
July 15, 2020
Immuno-Oncology News writes about Elicera's CAR T-cell program
Regulatory Press Release
Press Release
News
Read more
July 6, 2020
Financial Times writes about Elicera
Regulatory Press Release
Press Release
News
Read more
June 3, 2020
Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed
Regulatory Press Release
Press Release
News
Read more
April 23, 2020
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Regulatory Press Release
Press Release
News
Read more
April 2, 2020
Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers
Regulatory Press Release
Press Release
News
Read more
January 10, 2020
Funding from the Sjöberg Foundation
Regulatory Press Release
Press Release
News
Read more
November 13, 2019
Funding by the Swedish Cancer Society
Regulatory Press Release
Press Release
News
Read more
March 2, 2018
Status update by Uppsala University on the clinical phase I/II-study in NET
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
Swedish Public Radio interviews Professor Magnus Essand
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
The Medical Journal writes about a clinical study
Regulatory Press Release
Press Release
News
Read more
October 27, 2014
Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)
Regulatory Press Release
Press Release
News
Read more
June 15, 2013
Successful crowdfunding
Regulatory Press Release
Press Release
News
Read more
June 10, 2021
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 9, 2021
Elicera Therapeutics' new issue heavily oversubscribed
Regulatory Press Release
Press Release
News
Read more
June 4, 2021
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 3, 2021
CEO-interview by Nyhetsbyrån Direkt
Regulatory Press Release
Press Release
News
Read more
May 31, 2021
Article in "Forskning och framsteg"
Regulatory Press Release
Press Release
News
Read more
May 24, 2021
Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
May 18, 2021
Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.
Regulatory Press Release
Press Release
News
Read more
May 17, 2021
Company presentation at "Aktiedagen Göteborg".
Regulatory Press Release
Press Release
News
Read more
April 27, 2021
Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
April 15, 2021
Biostock writes about Elicera and CAR T-cells
Regulatory Press Release
Press Release
News
Read more
March 22, 2021
Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera Therapeutics recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 8, 2021
Elicera Therapeutics invitation to company presentation (in Swedish)
Regulatory Press Release
Press Release
News
Read more
October 20, 2020
Daily Mail writes about Elicera
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
July 15, 2020
Immuno-Oncology News writes about Elicera's CAR T-cell program
Regulatory Press Release
Press Release
News
Read more
July 6, 2020
Financial Times writes about Elicera
Regulatory Press Release
Press Release
News
Read more
June 3, 2020
Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed
Regulatory Press Release
Press Release
News
Read more
April 23, 2020
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Regulatory Press Release
Press Release
News
Read more
April 2, 2020
Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers
Regulatory Press Release
Press Release
News
Read more
January 10, 2020
Funding from the Sjöberg Foundation
Regulatory Press Release
Press Release
News
Read more
November 13, 2019
Funding by the Swedish Cancer Society
Regulatory Press Release
Press Release
News
Read more
March 2, 2018
Status update by Uppsala University on the clinical phase I/II-study in NET
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
Swedish Public Radio interviews Professor Magnus Essand
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
The Medical Journal writes about a clinical study
Regulatory Press Release
Press Release
News
Read more
October 27, 2014
Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)
Regulatory Press Release
Press Release
News
Read more
June 15, 2013
Successful crowdfunding
Regulatory Press Release
Press Release
News
Read more
June 10, 2021
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 9, 2021
Elicera Therapeutics' new issue heavily oversubscribed
Regulatory Press Release
Press Release
News
Read more
June 4, 2021
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 3, 2021
CEO-interview by Nyhetsbyrån Direkt
Regulatory Press Release
Press Release
News
Read more
May 31, 2021
Article in "Forskning och framsteg"
Regulatory Press Release
Press Release
News
Read more
May 24, 2021
Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
May 18, 2021
Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.
Regulatory Press Release
Press Release
News
Read more
May 17, 2021
Company presentation at "Aktiedagen Göteborg".
Regulatory Press Release
Press Release
News
Read more
April 27, 2021
Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
April 15, 2021
Biostock writes about Elicera and CAR T-cells
Regulatory Press Release
Press Release
News
Read more
March 22, 2021
Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera Therapeutics recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 8, 2021
Elicera Therapeutics invitation to company presentation (in Swedish)
Regulatory Press Release
Press Release
News
Read more
October 20, 2020
Daily Mail writes about Elicera
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
July 15, 2020
Immuno-Oncology News writes about Elicera's CAR T-cell program
Regulatory Press Release
Press Release
News
Read more
July 6, 2020
Financial Times writes about Elicera
Regulatory Press Release
Press Release
News
Read more
June 3, 2020
Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed
Regulatory Press Release
Press Release
News
Read more
April 23, 2020
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Regulatory Press Release
Press Release
News
Read more
April 2, 2020
Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers
Regulatory Press Release
Press Release
News
Read more
January 10, 2020
Funding from the Sjöberg Foundation
Regulatory Press Release
Press Release
News
Read more
November 13, 2019
Funding by the Swedish Cancer Society
Regulatory Press Release
Press Release
News
Read more
March 2, 2018
Status update by Uppsala University on the clinical phase I/II-study in NET
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
Swedish Public Radio interviews Professor Magnus Essand
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
The Medical Journal writes about a clinical study
Regulatory Press Release
Press Release
News
Read more
October 27, 2014
Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)
Regulatory Press Release
Press Release
News
Read more
June 15, 2013
Successful crowdfunding
Regulatory Press Release
Press Release
News
Read more
June 10, 2021
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 9, 2021
Elicera Therapeutics' new issue heavily oversubscribed
Regulatory Press Release
Press Release
News
Read more
June 4, 2021
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 3, 2021
CEO-interview by Nyhetsbyrån Direkt
Regulatory Press Release
Press Release
News
Read more
May 31, 2021
Article in "Forskning och framsteg"
Regulatory Press Release
Press Release
News
Read more
May 24, 2021
Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
May 18, 2021
Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.
Regulatory Press Release
Press Release
News
Read more
May 17, 2021
Company presentation at "Aktiedagen Göteborg".
Regulatory Press Release
Press Release
News
Read more
April 27, 2021
Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
April 15, 2021
Biostock writes about Elicera and CAR T-cells
Regulatory Press Release
Press Release
News
Read more
March 22, 2021
Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera Therapeutics recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 8, 2021
Elicera Therapeutics invitation to company presentation (in Swedish)
Regulatory Press Release
Press Release
News
Read more
October 20, 2020
Daily Mail writes about Elicera
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
July 15, 2020
Immuno-Oncology News writes about Elicera's CAR T-cell program
Regulatory Press Release
Press Release
News
Read more
July 6, 2020
Financial Times writes about Elicera
Regulatory Press Release
Press Release
News
Read more
June 3, 2020
Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed
Regulatory Press Release
Press Release
News
Read more
April 23, 2020
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Regulatory Press Release
Press Release
News
Read more
April 2, 2020
Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers
Regulatory Press Release
Press Release
News
Read more
January 10, 2020
Funding from the Sjöberg Foundation
Regulatory Press Release
Press Release
News
Read more
November 13, 2019
Funding by the Swedish Cancer Society
Regulatory Press Release
Press Release
News
Read more
March 2, 2018
Status update by Uppsala University on the clinical phase I/II-study in NET
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
Swedish Public Radio interviews Professor Magnus Essand
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
The Medical Journal writes about a clinical study
Regulatory Press Release
Press Release
News
Read more
October 27, 2014
Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)
Regulatory Press Release
Press Release
News
Read more
June 15, 2013
Successful crowdfunding
Regulatory Press Release
Press Release
News
Read more
June 10, 2021
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 9, 2021
Elicera Therapeutics' new issue heavily oversubscribed
Regulatory Press Release
Press Release
News
Read more
June 4, 2021
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 3, 2021
CEO-interview by Nyhetsbyrån Direkt
Regulatory Press Release
Press Release
News
Read more
May 31, 2021
Article in "Forskning och framsteg"
Regulatory Press Release
Press Release
News
Read more
May 24, 2021
Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
May 18, 2021
Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.
Regulatory Press Release
Press Release
News
Read more
May 17, 2021
Company presentation at "Aktiedagen Göteborg".
Regulatory Press Release
Press Release
News
Read more
April 27, 2021
Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
April 15, 2021
Biostock writes about Elicera and CAR T-cells
Regulatory Press Release
Press Release
News
Read more
March 22, 2021
Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera Therapeutics recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 8, 2021
Elicera Therapeutics invitation to company presentation (in Swedish)
Regulatory Press Release
Press Release
News
Read more
October 20, 2020
Daily Mail writes about Elicera
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
July 15, 2020
Immuno-Oncology News writes about Elicera's CAR T-cell program
Regulatory Press Release
Press Release
News
Read more
July 6, 2020
Financial Times writes about Elicera
Regulatory Press Release
Press Release
News
Read more
June 3, 2020
Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed
Regulatory Press Release
Press Release
News
Read more
April 23, 2020
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Regulatory Press Release
Press Release
News
Read more
April 2, 2020
Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers
Regulatory Press Release
Press Release
News
Read more
January 10, 2020
Funding from the Sjöberg Foundation
Regulatory Press Release
Press Release
News
Read more
November 13, 2019
Funding by the Swedish Cancer Society
Regulatory Press Release
Press Release
News
Read more
March 2, 2018
Status update by Uppsala University on the clinical phase I/II-study in NET
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
Swedish Public Radio interviews Professor Magnus Essand
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
The Medical Journal writes about a clinical study
Regulatory Press Release
Press Release
News
Read more
October 27, 2014
Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)
Regulatory Press Release
Press Release
News
Read more
June 15, 2013
Successful crowdfunding
Regulatory Press Release
Press Release
News
Read more
June 10, 2021
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 9, 2021
Elicera Therapeutics' new issue heavily oversubscribed
Regulatory Press Release
Press Release
News
Read more
June 4, 2021
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
June 3, 2021
CEO-interview by Nyhetsbyrån Direkt
Regulatory Press Release
Press Release
News
Read more
May 31, 2021
Article in "Forskning och framsteg"
Regulatory Press Release
Press Release
News
Read more
May 24, 2021
Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory Press Release
Press Release
News
Read more
May 18, 2021
Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.
Regulatory Press Release
Press Release
News
Read more
May 17, 2021
Company presentation at "Aktiedagen Göteborg".
Regulatory Press Release
Press Release
News
Read more
April 27, 2021
Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
April 15, 2021
Biostock writes about Elicera and CAR T-cells
Regulatory Press Release
Press Release
News
Read more
March 22, 2021
Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 11, 2021
Elicera Therapeutics recruits CFO
Regulatory Press Release
Press Release
News
Read more
January 8, 2021
Elicera Therapeutics invitation to company presentation (in Swedish)
Regulatory Press Release
Press Release
News
Read more
October 20, 2020
Daily Mail writes about Elicera
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing
Regulatory Press Release
Press Release
News
Read more
October 5, 2020
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
Regulatory Press Release
Press Release
News
Read more
July 15, 2020
Immuno-Oncology News writes about Elicera's CAR T-cell program
Regulatory Press Release
Press Release
News
Read more
July 6, 2020
Financial Times writes about Elicera
Regulatory Press Release
Press Release
News
Read more
June 3, 2020
Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed
Regulatory Press Release
Press Release
News
Read more
April 23, 2020
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Regulatory Press Release
Press Release
News
Read more
April 2, 2020
Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers
Regulatory Press Release
Press Release
News
Read more
January 10, 2020
Funding from the Sjöberg Foundation
Regulatory Press Release
Press Release
News
Read more
November 13, 2019
Funding by the Swedish Cancer Society
Regulatory Press Release
Press Release
News
Read more
March 2, 2018
Status update by Uppsala University on the clinical phase I/II-study in NET
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
Swedish Public Radio interviews Professor Magnus Essand
Regulatory Press Release
Press Release
News
Read more
December 12, 2016
The Medical Journal writes about a clinical study
Regulatory Press Release
Press Release
News
Read more
October 27, 2014
Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)
Regulatory Press Release
Press Release
News
Read more
June 15, 2013
Successful crowdfunding
Regulatory Press Release
Press Release
News
Read more
Sign up for Press Releases
By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy
here
.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept
